Best of ASCO 2024, Minneapolis

Minneapolis, MN US
June 15, 2024 to June 16, 2024

This CME-accredited oncology conference, Best of ASCO 2024, Minneapolis, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2024 ASCO® Annual Meeting (ASCO2024) in June 2024. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2024 into clinical contexts and discuss how the results may change the current standard of care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

ORGANIZING COMMITTEE: 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chair:

Siddhartha Yadav, MBBS, MD - Mayo Clinic

Associate Conference Chair:

Priya Kumar, MD - Health Partners

HOTEL RESERVATIONS

Attendees and supporters of this meeting can book their hotel room at the The Royal Sonesta Minneapolis Downtown at the discounted rate of $189/night + applicable taxes and fees. This rate is based on single occupancy and is valid three days before/after the meeting. The cut-off date is Wednesday, May 22, 2024. 

Click here to book your hotel room a the discounted rate.

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment
  4. Review abstracts presented at ASCO® 2024 and discuss their application in clinical settings

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 9.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 9.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 9.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.50 Contact Hours.
Course opens: 
12/06/2023
Course expires: 
08/31/2024
Event starts: 
06/15/2024 - 8:00am PDT
Event ends: 
06/16/2024 - 12:15pm PDT
Cost:
$350.00

DAY 1 - JUNE 15th, 2024


All times below are listed in Central Time (CT).

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:10 AM  Welcome


08:10 AM – 09:10 AM  Session 1 - Hematologic Malignancies 

Session Chair: Kurt C. Demel, MD

08:10 AM – 08:40 AM  Multiple Myeloma - Hamza Hashmi, MD

08:40 AM – 09:10 AM  Lymphoma & CLL - Parameswaran Venugopal, MD


09:10 AM – 09:40 AM  Global Oncology - Binay Shah, MD, MHA


09:40 AM – 10:10 AM  Break & Exhibits


10:10 AM – 11:40 AM  Session 2 - Thoracic Oncology

Session Chair: Yan Ji, MD

10:10 AM – 10:40 AM  Early-Stage NSCLC - Julian R. Molina, MD, PhD

10:40 AM – 11:10 AM  Metastatic NSCLC - Robert Kratzke MD

11:10 AM – 11:40 AM  Small Cell Lung Cancer - Rajat Thawani, MBBS


11:40 AM – 12:40 PM  Lunch & Exhibits


12:40 PM – 1:10 PM  Hormone Receptor-Positive Breast Cancer - David Potter, MD, PhD


1:10 PM – 02:10 PM  Session 3 - Case-Based Presentations 1

Session Chair: Priya Kumar, MBBS

01:10 PM – 01:30 PM  Case 1: Brain Tumor Updates - Sani H. Kizilbash, MD, MPH

01:30 PM – 01:50 PM  Case 2: Head and Neck Cancer - Manish Patel, DO

01:50 PM – 02:10 PM  Case 3: Palliative Care/Supportive Therapy - Aminah Jatoi, MD


02:10 PM – 02:30 PM  Break & Exhibits


02:30 PM – 04:00 PM  Session 4 - Genitourinary Cancer

Session Chair: Justin Hwang, PhD

02:30 PM – 03:00 PM  Prostate Cancer - Ulka Vaishampayan, MD

03:00 PM – 03:30 PM  Bladder Cancer -  Gautam Jha, MD

03:30 PM – 04:00 PM  Kidney Cancer - Nicholas Zorko, MD, PhD


DAY 2 - JUNE 16th, 2024
 

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 09:00 AM  Session 5 - Case-Based Presentations 2

Session Chair: Siddhartha Yadav, MBBS, MD

08:00 AM – 08:15 AM  Case 1: Ovarian Cancer - Siddhartha Yadav, MBBS, MD

08:15 AM – 08:30 AM  Case 2: Uterine/Cervical Cancer - Britt Erickson, MD

08:30 AM – 08:45 AM  Case 3: Breast Cancer - Binav Baral, MBBS

08:45 AM – 09:00 AM  Case 4: Breast Cancer - Dhauna Karam, MD, FACP

09:00 AM – 09:15 AM  Case 5: Sarcoma - Thanh P. Ho, MD

09:15 AM – 09:30 AM  Case 6: Cellular Therapy - Mithun Shah, MD, PhD


09:30 AM – 09:45 AM  Break & Exhibits


09:45 AM – 11:15 AM  Session 6 - GI Cancer

Session Chair: Balkrishna N. Jahagirdar, MBBS

09:45 AM – 10:15 AM  Colorectal Cancer - Joleen Hubbard, MD

10:15 AM – 10:45 AM  Hepatobiliary and Pancreatic Malignancies - Anup Kasi, MD, MPH

10:45 AM – 11:15 AM  Upper GI Cancer -  Ravi Kumar Paluri, MD, MPH


11:15 AM – 12:15 PM  Session 7 - Breast Cancer

Session Chair: Priya Kumar, MBBS

11:15 AM – 11:45 AM  HER2 Positive Breast Cancer - Dame W. Idossa, MD

11:45 AM – 12:15 PM  Triple Negative Breast Cancer - Roberto Leon-Ferre, MD


12:15 PM  Adjourn

The Royal Sonesta Minneapolis Downtown
35 S 7th St
Minneapolis, MN 55402
United States

HOTEL RESERVATIONS

Attendees and supporters of this meeting can book their hotel room at the The Royal Sonesta Minneapolis Downtown at the discounted rate of $189/night + applicable taxes and fees. This rate is based on single occupancy and is valid three days before/after the meeting. The cut-off date is Wednesday, May 22, 2024. 

Click here to book your hotel room a the discounted rate.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has a financial relationship (Other) with Repare Therapeutics;.
has a financial relationship (Other) with Astrazenca ;.
has a financial relationship (Other) with Astrazeneca ;.
Session Chair(s)

Kurt Demel, MD MBA

has no relevant financial relationships to disclose at this time.

Justin Hwang, PhD

has no relevant financial relationships to disclose at this time.

Balkrishna Jahagirdar, MBBS

has no relevant financial relationships to disclose at this time.

Yan Ji, MD, PhD, MS

has a financial relationship (Other) with AstraZeneca ;.
has a financial relationship (Other) with BMS;.

Priya Kumar

has no relevant financial relationships to disclose at this time.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has a financial relationship (Other) with Repare Therapeutics;.
has a financial relationship (Other) with Astrazenca ;.
has a financial relationship (Other) with Astrazeneca ;.
Speaker/Topic Presenter(s)

Hamza Hashmi, M.D., M.B.B.S.

has a financial relationship (Independent contractor) with JANSSEN;.
has a financial relationship (Independent contractor) with KARYOPHARM;.
has a financial relationship (Independent contractor) with AMGEN;.

Joleen Hubbard, MD

has a financial relationship (Other) with Merck;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with TriOncology;.
has a financial relationship (Grant Or Contract) with Trovogene;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Pionyr Immunotherapeutics;.
has a financial relationship (Other) with BeiGene;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Hutchison Medipharma;.
has a financial relationship (Grant Or Contract) with Roche;.
has a financial relationship (Other) with Bayer;.
has a financial relationship (Grant Or Contract) with Treos Bio;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with G1 Therapeutics;.

Damé Idossa

has no relevant financial relationships to disclose at this time.

Gautam Jha

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Exelexis;.

Anup Kasi, MD MPH

has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Grant Or Contract) with Cardiff;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Novocure;.
has a financial relationship (Professional Services) with Cardinal Health;.
has a financial relationship (Grant Or Contract) with Ability;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Grant Or Contract) with Lisata;.
has a financial relationship (Grant Or Contract) with Panavance Therapeutics;.

Robert Kratzke, Professor of Medicine

has a financial relationship (Professional Services) with Mirati;.

Roberto Leon-Ferre

has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Lyell;.
has a financial relationship (Other) with AstraZeneca;.

Julian Molina

has no relevant financial relationships to disclose at this time.

Ravi Paluri, MD MPH FACP

has a financial relationship (Professional Services) with IPSEN;.
has a financial relationship (Professional Services) with EXELIXIS;.

David Potter, MD, PhD

has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Innocrin Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with ALX Oncology;.
has a financial relationship (Grant Or Contract) with ImmunoMet Therapeutics;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with Dava Oncology;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Grant Or Contract) with Spectrum Pharmaceuticals;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Quantum Leap Health Collaborative;.

Rajat Thawani, MD

has no relevant financial relationships to disclose at this time.

Ulka Vaishampayan, MD

has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with sanofi;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Gilead;.

Parameswaran Venugopal, MD

has a financial relationship (Professional Services) with BeiGene;.

Nicholas Zorko, MD, PhD

has a financial relationship (Other) with Telix Pharmaceuticals;.
has a financial relationship (Other) with Caris Life Sciences ;.
Case Presenter(s)

Binav Baral, MBBS

has no relevant financial relationships to disclose at this time.

Britt Erickson

has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Immunogen;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Professional Services) with AstraZeneca;.

Thanh Ho

has no relevant financial relationships to disclose at this time.

Aminah Jatoi, M.D.

has a financial relationship (Travel) with Pfizer;.

Dhauna Karam, MBBS, MD, FACP

has no relevant financial relationships to disclose at this time.

Sani Kizilbash, MD, MPH

has no relevant financial relationships to disclose at this time.

Manish Patel

has a financial relationship (Grant Or Contract) with Merck, Sharpe, and Dohme;.
has a financial relationship (Grant Or Contract) with Astra-Zeneca;.

Mithun Shah, MD, PhD

has a financial relationship (Grant Or Contract) with KURA Oncology;.
has a financial relationship (Grant Or Contract) with Celgene;.
has a financial relationship (Grant Or Contract) with MRKR Therapeutics;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Grant Or Contract) with Astellas;.
Moderator(s)

Kurt Demel, MD MBA

has no relevant financial relationships to disclose at this time.

Justin Hwang, PhD

has no relevant financial relationships to disclose at this time.

Yan Ji, MD, PhD, MS

has a financial relationship (Other) with AstraZeneca ;.
has a financial relationship (Other) with BMS;.
Planning committee(s)

Priya Kumar

has no relevant financial relationships to disclose at this time.

Available Credit

  • 9.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 9.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 9.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.